Brind.

CRISPR Therapeutics Names A.J. Silver as New Chief Financial Officer

1 report, 1 independent Updated Oct 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

CRISPR Therapeutics announced that Raju Prasad will step down from his role as Chief Financial Officer to pursue external opportunities. A.J. Silver, the company's Senior Vice President of Finance, will succeed Dr. Prasad as CFO, with the transition effective immediately. Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics, welcomed A.J. Silver to the role.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The transition brings new leadership to manage the financial operations and investor relations of CRISPR Therapeutics. A.J. Silver previously worked at Ernst & Young LLP, and his appointment is noted as a key leadership change within the company's finance organization.

From manilatimes.net

Who's involved

  • CRISPR TherapeuticsThe company appointing the new Chief Financial Officer.
  • A.J.The incoming Chief Financial Officer, who was previously employed by Ernst & Young LLP.
  • Ernst & Young LLPThe firm where A.J. Silver was historically employed.

Possible ripples

Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped